The Role of Enhancers in Cancer

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2016 Jul 2

PMID 27364481

Citations 206

Authors

Inderpreet Sur

Jussi Taipale

Affiliations

Soon will be listed here.

Abstract

Enhancer elements function as the logic gates of the genetic regulatory circuitry. One of their most important functions is the integration of extracellular signals with intracellular cell fate information to generate cell type-specific transcriptional responses. Mutations occurring in cancer often misregulate enhancers that normally control the signal-dependent expression of growth-related genes. This misregulation can result from trans-acting mechanisms, such as activation of the transcription factors or epigenetic regulators that control enhancer activity, or can be caused in cis by direct mutations that alter the activity of the enhancer or its target gene specificity. These processes can generate tumour type-specific super-enhancers and establish a 'locked' gene regulatory state that drives the uncontrolled proliferation of cancer cells. Here, we review the role of enhancers in cancer, and their potential as therapeutic targets.

Citing Articles

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.

Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X Cell Death Discov. 2025; 11(1):84.

PMID: 40032852 PMC: 11876437. DOI: 10.1038/s41420-025-02366-3.

The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.

Bayraktar R, Tang Y, Dragomir M, Ivan C, Peng X, Fabris L Sci Adv. 2025; 11(8):eado2830.

PMID: 39970212 PMC: 11837999. DOI: 10.1126/sciadv.ado2830.

Comprehensive dissection of cis-regulatory elements in a 2.8 Mb topologically associated domain in six human cancers.

Caragine C, Le V, Mustafa M, Diaz B, Morris J, Muller S Nat Commun. 2025; 16(1):1611.

PMID: 39948336 PMC: 11825950. DOI: 10.1038/s41467-025-56568-5.

Super-enhancers in tumors: unraveling recent advances in their role in Oncogenesis and the emergence of targeted therapies.

Ji Y, Li B, Lin R, Yuan J, Han Y, Du Y J Transl Med. 2025; 23(1):98.

PMID: 39838405 PMC: 11753147. DOI: 10.1186/s12967-025-06098-x.

Study of the Anti-MYC Potential of Lanostane-Type Triterpenes.

Oliveira J, Negreiro J, Nunes F, Barbosa F, Mafezoli J, Mattos M ACS Omega. 2025; 9(51):50844-50858.

PMID: 39741863 PMC: 11683602. DOI: 10.1021/acsomega.4c10201.

References

Albert F, Kruglyak L . The role of regulatory variation in complex traits and disease. Nat Rev Genet. 2015; 16(4):197-212. DOI: 10.1038/nrg3891. View

Sharpe J, Nonchev S, Gould A, Whiting J, Krumlauf R . Selectivity, sharing and competitive interactions in the regulation of Hoxb genes. EMBO J. 1998; 17(6):1788-98. PMC: 1170526. DOI: 10.1093/emboj/17.6.1788. View

Heintzman N, Stuart R, Hon G, Fu Y, Ching C, Hawkins R . Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007; 39(3):311-8. DOI: 10.1038/ng1966. View

Plass C, Pfister S, Lindroth A, Bogatyrova O, Claus R, Lichter P . Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet. 2013; 14(11):765-80. DOI: 10.1038/nrg3554. View

Hnisz D, Abraham B, Lee T, Lau A, Saint-Andre V, Sigova A . Super-enhancers in the control of cell identity and disease. Cell. 2013; 155(4):934-47. PMC: 3841062. DOI: 10.1016/j.cell.2013.09.053. View

Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T . The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet. 2009; 41(8):885-90. DOI: 10.1038/ng.406. View

Gudmundsson J, Sulem P, Manolescu A, Amundadottir L, Gudbjartsson D, Helgason A . Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007; 39(5):631-7. DOI: 10.1038/ng1999. View

Bell O, Tiwari V, Thoma N, Schubeler D . Determinants and dynamics of genome accessibility. Nat Rev Genet. 2011; 12(8):554-64. DOI: 10.1038/nrg3017. View

Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A . Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A. 2016; 113(13):E1826-34. PMC: 4822610. DOI: 10.1073/pnas.1519286113. View

10.

Kumar K, Raza S, Knab L, Chow C, Kwok B, Bentrem D . GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep. 2015; 5:9489. PMC: 4452877. DOI: 10.1038/srep09489. View

11.

Hindorff L, Sethupathy P, Junkins H, Ramos E, Mehta J, Collins F . Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009; 106(23):9362-7. PMC: 2687147. DOI: 10.1073/pnas.0903103106. View

12.

Tak Y, Hung Y, Yao L, Grimmer M, Do A, Bhakta M . Effects on the transcriptome upon deletion of a distal element cannot be predicted by the size of the H3K27Ac peak in human cells. Nucleic Acids Res. 2016; 44(9):4123-33. PMC: 4872074. DOI: 10.1093/nar/gkv1530. View

13.

Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

14.

Melton C, Reuter J, Spacek D, Snyder M . Recurrent somatic mutations in regulatory regions of human cancer genomes. Nat Genet. 2015; 47(7):710-6. PMC: 4485503. DOI: 10.1038/ng.3332. View

15.

Loven J, Hoke H, Lin C, Lau A, Orlando D, Vakoc C . Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153(2):320-34. PMC: 3760967. DOI: 10.1016/j.cell.2013.03.036. View

16.

Stadler M, Murr R, Burger L, Ivanek R, Lienert F, Scholer A . DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature. 2011; 480(7378):490-5. DOI: 10.1038/nature10716. View

17.

Stormo G, Zhao Y . Determining the specificity of protein-DNA interactions. Nat Rev Genet. 2010; 11(11):751-60. DOI: 10.1038/nrg2845. View

18.

Mansour M, Abraham B, Anders L, Berezovskaya A, Gutierrez A, Durbin A . Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014; 346(6215):1373-7. PMC: 4720521. DOI: 10.1126/science.1259037. View

19.

Hnisz D, Weintraub A, Day D, Valton A, Bak R, Li C . Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 2016; 351(6280):1454-1458. PMC: 4884612. DOI: 10.1126/science.aad9024. View

20.

Polak P, Karlic R, Koren A, Thurman R, Sandstrom R, Lawrence M . Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature. 2015; 518(7539):360-364. PMC: 4405175. DOI: 10.1038/nature14221. View